Home > News
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
Individuals with cancer, particularly those who are receiving systemic anticancer treatments, have been postulated to be at increased risk of mortality from COVID-19. This conjecture has considerable effect on the treatment of patients with cancer and data from large, multicentre studies to support this assumption are scarce because of the contingencies of the pandemic. We aimed to describe the clinical and demographic characteristics and COVID-19 outcomes in patients with cancer.
Mortality from COVID-19 in cancer patients appears to be principally driven by age, gender, and
comorbidities. We are not able to identify evidence that cancer patients on cytotoxic chemotherapy or other
anticancer treatment are at an increased risk of mortality from COVID-19 disease compared with those not on
active treatment.